Navigation Links
Evolution Hematology System

ProductsEvolution Hematology System
Company Drew Scientific
Item Evolution Hematology System
Features 
  • Accepts most commonly used closed collection tubes
  • 16 parameters with 3 histograms
  • Innovative capillary mode, no need for external pre-dilution
  • 60 samples per hour in closed tube mode
  • Sample size flexibility satisfies a wide range of end user requirements
  • Large LCD with histograms on screen
  • User friendly operator interface
  • Data management stores up to 200 sample records with histograms
Description Drew Scientific has been making leading edge, top quality CBC systems for over 15 years. The Evolution offers all the features of the Excell 16 with the new addition of primary sample tube cap piercing.
Info Drew Scientific
Customer Service: 800-807-1786
Web site: http://www.drew-scientific.com

Related medicine products :

1. STA-R Evolution
2. Spine System Evolution
3. Evolution Vision Diagnostic System
4. ULTRA Evolution Multi-Detection Microplate Reader
5. Roche/STAGO STA-R Evolution®
6. Coulter LH 755 Hematology Workcell
7. Coulter LH 750 Hematology Analyzer
8. COULTER LH 755 Hematology Workcell
9. COULTER LH 750 Hematology Analyzer
10. COULTER MAXM Hematology Analyzer
11. COULTER HmX Hematology Analyzer
Alloclassic Hip
Perfecta RS Stems
S-ROM Femoral Stems - XX-Long Length Stems 36mm Neck with 21mm Calcar Replacement + Lat Neck
S-ROM Femoral Stems - Long Length Stems Standard 36mm Neck
Medicine Products:
(Date:12/2/2009)...Constraint-induced movement therapy (CIMT) is a po...ren with hemiplegic cerebral palsy, but more resea...w published in the November issue of Physical The...n Physical Therapy Association (APTA). The review,...ematic reviews, concluded that further research sh...
(Date:12/2/2009)... Revolutionary new cell phones that direct ...l be available in early 2010 from Aerius Internati...mber 2, 2009 -- Revolutionary new cell phones that...sers will be available in early 2010 from Aerius I...red with a Green Technology Award in wireless comm...
(Date:12/2/2009)... A team of Kendall Hunt authors earned the ...d at the recent National Association for Gifted Ch...ember 5-7, 2009. , Dubuqu...l Hunt authors earned the 2009 Gifted Child Quarte... Association for Gifted Children’s annual co...
(Date:12/2/2009)...HINGTON, Dec. 2 Pro-abo..., December 2 in their campaign against the U.S. Ho... Americans United for Life President and CEO Charm...the abortion lobby,s effort to expand taxpayer fun...h health care, the feminist groups and the abortio...
(Date:12/2/2009)...S ANGELES, Dec. 2 At a ...Tourism ministerial delegates came together to out...equired to give it the necessary thrust. Organized...edicaltourismassociation.com , the high-powered co...iscussed the opportunities and requests for assist...
Breaking Medicine News(10 mins):Health News:Report shows CIMT may improve arm use in children with hemiplegic cerebral palsy 2Health News:New AERIUS Cell Phones Direct Microwave Signals Away from Users 2Health News:Kendall Hunt Authors Earn NAGC “Paper of the Year” Award 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 2Health News:Ministerial Roundtable Discusses Future of Medical Tourism 3
...A hospital in Chennai has created history by succe...ant in an eight-year-old Ugandan boy using the co...on of what the procedure would cost internationall...ht to the Apollo Specialty Hospital here. ...
...Three gene variants in the DNA of 486 AIDS patient...the HIV virus, according to research published Th... will lead to a vaccine that would boost the prote...mising, the scientists said in a study to appear i...
...A British woman will be aiming to raise awareness ...y when she sets out on a solo row across the Pacif...Roz Savage, 38, has already traversed the Atlantic... across the vast expanse of the Pacific. S...
...Madrid is the culinary melting pot of a country wh...rld by the New York Times, the author of a new boo...here is no real Madrid cooking but that's because ...novative cooking in Madrid). Rincon came u...
...Supermodel Petra Nemcova turned vegetarian to help...gave up meat and dairy products in February after ... "I read that if we fish the way we fish, ... star insisted that that she felt a 'strong connec...
...Burlesque star Dita Von Teese says that she often ... healthy hobby to be a voyeur. The estran...ur pornography has something to offer to almost ev... She insists that she is just like other people ...
Other Medicine News:Health News:Chennai Hospital Conducts Bone Marrow Transplantation Successfully 2Health News:Three Gene Variants Could Hold Key for HIV Vaccine: Study 2Health News:Briton Set for Pacific Solo Odyssey to Highlight Warming 2
(Date:12/2/2009)... , PLEASANTON, Calif., Dec. 2 /PRNewswire-Firs...nced today that the United States Food & Drug ...ed use for its licensed nucleic acid test, to scre...dividual donations. The test, called the cobas... system, is a qualitative, in-vitro test for the s...
(Date:12/2/2009)... , NANJING, China, Dec. 2 /PRNewswire-...r the "Company") (NYSE: SCR ), a leading pharmac...anufacturing, and marketing of branded,generic and...ted that its,subsidiary Jiangsu Yanshen Biological...s suspended production of all its products in orde...
(Date:12/2/2009)... , EAST HANOVER, N.J., Dec. 2 /PRNewsw...cluding a late-breaking presentation on Tasigna...ic myeloid leukemia, demonstrate the strength of t... care of patients. ,, The new data, at the 51s...ing and Exposition, highlight the company,s curren...
Breaking Medicine Technology:FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 2FDA Approves Use of Roche Test to Screen Source Plasma for HIV, Hepatitis B Virus and Hepatitis C Virus 3Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 2Simcere Pharmaceutical Group Announces Jiangsu Yanshen's Voluntary Suspension of Production 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Brain computer interface developed at Brown begins new clinical trial 8783 1Brain computer interface developed at Brown begins new clinical trial 8783 2Brain computer interface developed at Brown begins new clinical trial 8783 3Brain computer interface developed at Brown begins new clinical trial 8783 4Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 1Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 2Published Study Shows VNUS ClosureFAST 26amp 3B 238482 3B System Significantly Superior to Laser for Varicose Vein Treatment 48411 3Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 1Forterus Inc Announces Special Board Meeting 3B Nominates Jeff Walton Former Bear Stearns President to Board of Directors 48408 2